Cerevel Therapeutics Holdings, Inc.
cerevel.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 8, 2024. Its latest SEC filing is a 15-12G from Aug 12, 2024.
10-Q for Q1 FY2024, filed May 8, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops potential medicines for people with neurological and psychiatric conditions, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease.
10-K for FY2023, filed Feb 27, 2024We are a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2023, filed Feb 27, 2024
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2024, filed May 8, 2024
−$131.9MView ↗
- ▲ +26% (Loss)
- vs −$104.3M in Q1 FY2023
-
Aug 1, 2024
AbbVie completed its acquisition of Cerevel
Cerevel became a wholly owned subsidiary of AbbVie.
Sources
8-K, filed Aug 1, 2024
On August 1, 2024, the Merger was completed. Upon the consummation of the Merger, Cerevel became a wholly owned subsidiary of AbbVie.View ↗
Target conditions expanded The earlier business description names schizophrenia, epilepsy and Parkinson’s disease; the latest also names Alzheimer’s disease psychosis and panic disorder among the conditions its candidates target.
Who Did They Compete With?
Competes with Otsuka Holdings, Johnson & Johnson, Alkermes, Eli Lilly, Intra-Cellular Therapies, Sumitomo Dainippon Pharma, Acadia Pharmaceuticals, Minerva Neurosciences, Neurocrine Biosciences, Karuna Therapeutics, SK Life Sciences, Xenon Pharmaceuticals, Engrail Therapeutics, Avenue Therapeutics, UCB, Marinus Pharmaceuticals, Jazz Pharmaceuticals, Medtronic, St. Jude Medical, and Denali Therapeutics
10-K for FY2023, filed Feb 27, 2024We are developing emraclidine for the treatment of schizophrenia. While there remains significant unmet need in schizophrenia, we may face…View ↗
Loading...
